BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Coverage Initiated by Analysts at JPMorgan Chase & Co.

JPMorgan Chase & Co. assumed coverage on shares of BridgeBio Oncology Therapeutics (NASDAQ:BBOT) in a report published on Wednesday, MarketBeat.com reports. The brokerage issued an overweight rating and a $27.00 target price on the stock.

A number of other research firms also recently weighed in on BBOT. Oppenheimer assumed coverage on shares of BridgeBio Oncology Therapeutics in a research note on Monday, June 22nd. They set an “outperform” rating and a $22.00 price target on the stock. Canaccord Genuity Group assumed coverage on shares of BridgeBio Oncology Therapeutics in a research note on Monday, May 11th. They set a “buy” rating and a $23.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of BridgeBio Oncology Therapeutics in a report on Thursday, June 18th. Wall Street Zen lowered BridgeBio Oncology Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. Finally, UBS Group cut BridgeBio Oncology Therapeutics to an “overweight” rating in a report on Wednesday. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $24.80.

BridgeBio Oncology Therapeutics Stock Up 8.8%

BBOT opened at $9.02 on Wednesday. BridgeBio Oncology Therapeutics has a 12 month low of $7.00 and a 12 month high of $14.87. The company has a 50-day simple moving average of $8.10. The stock has a market cap of $722.59 million, a PE ratio of -4.40 and a beta of 0.39.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) last released its earnings results on Tuesday, May 12th. The company reported ($526.11) earnings per share (EPS) for the quarter. Equities research analysts predict that BridgeBio Oncology Therapeutics will post -2.33 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Avidity Partners Management LP purchased a new stake in shares of BridgeBio Oncology Therapeutics in the first quarter worth about $392,000. Granahan Investment Management LLC acquired a new stake in shares of BridgeBio Oncology Therapeutics in the first quarter valued at about $2,068,000. Renaissance Technologies LLC raised its holdings in shares of BridgeBio Oncology Therapeutics by 37.1% during the 1st quarter. Renaissance Technologies LLC now owns 101,900 shares of the company’s stock valued at $912,000 after buying an additional 27,600 shares during the period. XTX Topco Ltd raised its holdings in shares of BridgeBio Oncology Therapeutics by 22.4% during the 4th quarter. XTX Topco Ltd now owns 28,633 shares of the company’s stock valued at $358,000 after buying an additional 5,249 shares during the period. Finally, Quadrature Capital Ltd acquired a new position in BridgeBio Oncology Therapeutics during the 4th quarter worth approximately $162,000. 54.89% of the stock is owned by hedge funds and other institutional investors.

About BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.